An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
aTyr Pharma to Present at November Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
aTyr Pharma, Inc. (Nasdaq: LIFE) will present at two investor conferences in November 2023. The first is the Jefferies London Healthcare Conference on November 15 in London, UK, and the second is the Piper Sandler 35th Annual Healthcare Conference on November 30 in New York, NY. The company's management will also be available for one-on-one meetings with investors. Webcasts of each event will be available on the company's website, and replays will be accessible for at least 90 days.
Positive
None.
Negative
None.
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at two upcoming investor conferences scheduled to take place in November 2023.
Details of the presentations appear below:
Conference: Jefferies London Healthcare Conference Date: Wednesday, November 15, 2023 Time: 3:30pm GMT Location: London, UK Format: Corporate Presentation
Conference: Piper Sandler 35th Annual Healthcare Conference Date: Thursday, November 30, 2023 Time: 12:00pm EST Location: New York, NY Format: Fireside Chat
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. A webcast of each event will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the events, a replay of the presentations will be available on the aTyr website for at least 90 days.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Contact: Ashlee Dunston Director, Investor Relations and Public Affairs adunston@atyrpharma.com
FAQ
When and where will aTyr Pharma be presenting at investor conferences in November 2023?
aTyr Pharma will be presenting at the Jefferies London Healthcare Conference on November 15 in London, UK, and at the Piper Sandler 35th Annual Healthcare Conference on November 30 in New York, NY.
Will aTyr Pharma's management be available for meetings with investors?
Yes, aTyr Pharma's management will be available for one-on-one meetings with investors who are registered attendees of the conferences.
Where can I find webcasts of the presentations?
Webcasts of the presentations will be available on the Investor's section of aTyr Pharma's website at www.atyrpharma.com.
How long will the replays of the presentations be available?
Replays of the presentations will be available on aTyr Pharma's website for at least 90 days.
What is aTyr Pharma's lead therapeutic candidate?
aTyr Pharma's lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease.
What is interstitial lung disease?
Interstitial lung disease is a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs.
What is aTyr Pharma's focus in drug discovery?
aTyr Pharma leverages evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.
What is aTyr Pharma's discovery platform based on?
aTyr Pharma's discovery platform is based on uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases.
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation
